Moonwalk Biosciences founding team (L-R): CEO Alex Aravanis, COO Justin Valley, CBO Elaine Cheung, and president and CTO Arash Jamshidi. (Photo credit: Erin Beach)

January 4, 2024 08:00 AM EST

Cell/Gene Tx

Backed by CRISPR pioneer Feng Zhang, epigenetics biotech Moonwalk debuts with $57M

Ayisha Sharma

News Reporter

Moonwalk Biosciences has secured $57 million in seed and Series A funds to advance its epigenetics platform and preclinical pipeline in the latest endeavor by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Backed by CRISPR pioneer Feng Zhang, epigenetics biotech Moonwalk debuts with $57M

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Backed by CRISPR pi­o­neer Feng Zhang, epi­ge­net­ics biotech Moon­walk de­buts with $57M

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Backed by CRISPR pioneer Feng Zhang, epigenetics biotech Moonwalk debuts with $57M

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?